Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Randomized (2:1) multi-center open-label phase II trial. Patients with high-risk SMM will be
enrolled on the study and treated with KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2,
lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9) or Rd combination
(Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9);
followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
Phase:
Phase 2
Details
Lead Sponsor:
Stichting Hemato-Oncologie voor Volwassenen Nederland